Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stempeutics inaugurates second stem cell lab

This article was originally published in Scrip

Executive Summary

Stempeutics Research, part of India's Manipal Education and Medical Group, has inaugurated its second stem cell research and therapeutics lab at the Manipal University campus. The facility will be used for advanced stem cell research in human embryonic stem cells in collaboration with Manipal Assisted Reproduction Center. Stempeutics expects to conduct pilot studies to address the needs of patients with dilated cardiomyopathy, end stage liver disease and osteoarthritis. It also expects to establish large scale production of mesenchymal stem cells for clinical trials using an innovative upscaling process. Stempeutics, which aims to develop allogenic stem cell therapy in the future, currently focuses on bone marrow derived adult mesenchymal stem cells. The company's initial emphasis is on autologous cell therapies – where the bone marrow is aspirated from the patient, stem cells are isolated and upscaled and then injected back to the patient. Stempeutics is also setting up its third lab at Kuala Lumpur, which it expects to be operational in August.

Topics

UsernamePublicRestriction

Register

SC003131

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel